L. H. van der Helm

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.

Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.

E. Vellenga, A. A. van de Loosdrecht, G. Huls, 2013, Leukemia research.

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

G. Ossenkoppele, C. Eeltink, A. A. van de Loosdrecht, 2014, Cytometry. Part B, Clinical cytometry.

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

E. van den Berg, E. Vellenga, G. Huls, 2013, Journal of Hematology & Oncology.

Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.

E. van den Berg, E. Vellenga, G. D. de Bock, 2019, Leukemia research.

Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.

E. van den Berg, E. Vellenga, G. D. de Bock, 2019, Leukemia research.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.